OBM Neurobiology is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc. By design, the scope of OBM Neurobiology is broad, so as to reflect the multidisciplinary nature of the field of Neurobiology that interfaces biology with the fundamental and clinical neurosciences. As such, OBM Neurobiology embraces rigorous multidisciplinary investigations into the form and function of neurons and glia that make up the nervous system, either individually or in ensemble, in health or disease. OBM Neurobiology welcomes original contributions that employ a combination of molecular, cellular, systems and behavioral approaches to report novel neuroanatomical, neuropharmacological, neurophysiological and neurobehavioral findings related to the following aspects of the nervous system: Signal Transduction and Neurotransmission; Neural Circuits and Systems Neurobiology; Nervous System Development and Aging; Neurobiology of Nervous System Diseases (e.g., Developmental Brain Disorders; Neurodegenerative Disorders).
OBM Neurobiology publishes research articles, technical reports and invited topical reviews. Although the OBM Neurobiology Editorial Board encourages authors to be succinct, there is no restriction on the length of the papers. Authors should present their results in as much detail as possible, as reviewers are encouraged to emphasize scientific rigor and reproducibility.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 7.6 days from acceptance to publication (median values for papers published in this journal in 2020, 1-2 days of FREE language polishing time is also included in this period).
Recent Advances in Diagnosis and Therapy of Neuromuscular Disorders
Submission Deadline: April 30, 2021 (Open) Submit Now
Tai-Heng Chen, MD, MMedSc
Assistant Professor, Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
Research Interests: Pediatric neurology; Developmental neuroscience; Neurosciences ; Neuromuscular disorders; Motor neuron disease; Spinal muscular atrophy
About This Topic
Neuromuscular disorders are a diverse group of conditions that affect one in about 2000 individuals worldwide. With the advances in genetic medicine, clinicians now can apply novel molecular approaches to identify new syndromes quickly, and in many cases, expand our understanding of known and unknown neuromuscular affections. This advance has also led to the development of specific therapies. For example, gene therapy and other molecular-based therapies are now entering our clinics as treatments for spinal muscular atrophy, malnutrition, and other genetically determined neuromuscular diseases. For many other diseases, specific treatments still exist, but they may soon become a reality. In the past ten years, through expanded cooperation between medical centers around the world, as well as cooperation between patient and parent support groups, academia, industry, and government, it has promoted the identification of specific syndromes and new treatments for pediatric neuromuscular diseases Development. These coordinated actions have accelerated the search for effective treatments and unified the standards of care on a global scale. In this topic section, we welcome the studies, perspectives, and comments on recent advances that will transform the clinical approach from reactive (identifying phenotypes) to proactive (to gene-based precise medicine) in the coming future.
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.